Life sciences companies continue to face a myriad of requirements to ensure compliance with a highly regulated industry environment. As businesses innovate in a digital and data-driven world, the interplay between health and data regulations is becoming increasingly complex and challenging.
Explore Data PULSE, a platform that helps you to navigate the complex landscape of data, regulatory and IP protection concerns throughout various stages of the medical product life cycle.
The Data PULSE platform identifies some key issues to mitigate risk and optimize business strategies during the R&D, market authorization and post-market study stages. Navigating these intricate and interlinked laws is crucial to provide better patient care, develop new products, mitigate risk and avoid compliance failures.
 |
 |
 |
 |
|||
For a focused discussion, please contact us or reach out to a key contact in your region listed below:
Key Contacts
|
Asia Pacific Anne-Marie Allgrove Kherk Ying Chew Divina Ilas-Panganiban Marcia Lee Ren Jun Lim Toby Patten Vivian Wu |
EMEA Martin Altschwager Elisabeth Dehareng Nathalja Doing Francesca Gaudino Julia Gillert Els Janssens Patricia Perez Soto Florian Tannen Jaspreet Takhar Julie Yeni |
|
Latin America Flavia Amaral Vanina Caniza Diego Ferrada Roberto Grané María Eugenia Salazar Furiati Teresa Tovar |
North America Brian Hengesbaugh Theo Ling Christian Alejandro Lopez-Silva Cristina Messerschmidt Carlos Vela |
* FenXun established a joint operation office with Baker McKenzie in China as Baker McKenzie FenXun, which was approved by the Shanghai Justice Bureau in 2015.
** Trench Rossi Watanabe and Baker McKenzie have executed a strategic cooperation agreement for consulting on foreign law